Therapeutic area
Infectious disease and vaccines
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations
Approvals since 2023
33
Originals, plus breakthrough or accelerated new uses
Recruiting Phase 2
88
Industry-sponsored
Recruiting Phase 3
66
Industry-sponsored
Recruiting Phase 4 (post-approval)
11
Industry-sponsored
Recent approvals
- Hibsago (Bepirovirsen Sodium) · Glaxosmithkline NovelPriority reviewOct 20, 2026
To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy
- Hovilpri (Pritelivir Mesylate) · Aicuris Anti-Infect NovelPriority reviewOct 9, 2026
To treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies
- Utebzi (Tebipenem Pivoxil Hydrobromide) · Glaxosmithkline NovelPriority reviewJun 17, 2026
To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options
- Zaynich (Cefepime Hydrochloride, Zidebactam) · Wockhardt Bio AG NovelPriority reviewMay 29, 2026
To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms
- Xocova (Ensitrelvir) · Shionogi NovelMay 29, 2026
To use as post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) following contact with an individual who has COVID-19
- Hepcludex (Bulevirtide-Gmod) · Gilead Sciences INC NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanMay 22, 2026
To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis
- Idvynso (Doravirine, Islatravir) · Msd NovelApr 20, 2026
To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine
- Favlyxa (Fluorouracil) · Avyxa Holdings Feb 20, 2026
- Nuzolvence (Zoliflodacin) · Entasis Therap NovelPriority reviewDec 12, 2025
To treat uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae
- Clotic (Clotrimazole) · Carwin Pharm Assoc Priority reviewOrphanSep 26, 2025
- Inlexzo (Gemcitabine Hydrochloride) · Janssen Biotech Breakthrough therapyPriority reviewSep 9, 2025
- Mavyret (Glecaprevir, Pibrentasvir) · Abbvie Breakthrough therapyPriority reviewOrphanJun 10, 2025
- Mavyret (Glecaprevir, Pibrentasvir) · Abbvie Breakthrough therapyPriority reviewOrphanJun 10, 2025
- Enflonsia (Clesrovimab-Cfor) · Merck Sharp Dohme NovelPriority reviewJun 9, 2025
To prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season
- Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTD Apr 30, 2025
Recruiting trials by phase
Industry-sponsored drug and biologic trials.
Most approvals since then, by company
- GSK3
Drugs in development
Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- PovorcitinibINCB054707, INCB54707Phase 312 trials
Incyte · Hidradenitis Suppurativa (HS), NonSegmental Vitiligo, Prurigo Nodularis
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- CHO Cellrecombinant zoster vaccine, Recombinant Respiratory Syncytial Virus VaccinePhase 39 trials
MAXVAX Biotechnology Limited Liability Company · Herpes Zoster, Respiratory Syncytial Virus (RSV), Herpes Zoster (HZ)
- BCGPhase 38 trials
ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis
- ElebsiranVIR-2218, BRII-835Phase 38 trials
Vir Biotechnology, Inc. · Viral Hepatitis, Hepatitis D, Chronic, Chronic Hepatitis B Virus (HBV) Infection
- IBI362Phase 38 trials
Innovent Biologics (Suzhou) Co. Ltd. · Obesity, Overweight, Sleep Apnea
- RSVpreFRESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE, PF-06928316Phase 38 trials
Pfizer · Respiratory Syncytial Virus (RSV), Lower Respiratory Tract Illness, Adult
- EfimosferminBOS-580Phase 37 trials
GSK · Non-alcoholic Fatty Liver Disease, Metabolic Dysfunction-associated Steatohepatitis, Liver Diseases, Alcoholic
- Active Comparator vaccinePhase 36 trials
Sinovac Biotech Co., Ltd · Epidemic Meningitis, Meningococcal Vaccines, Herpes Zoster
- PPV2323-valent Pneumococcal Polysaccharide Vaccine, lot 1Phase 36 trials
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Healthy Volunteers, Streptococcus Pneumoniae Infection, Pneumococcal Disease
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- HydronidoneF351Phase 35 trials
Beijing Continent Pharmaceutical Co, Ltd. · Liver Fibrosis, Chronic Hepatitis B With Hepatic Fibrosis, Liver Fibrosis in Chronic Hepatitis B
- RaphaminMMH-407Phase 35 trials
Materia Medica Holding · Rhinosinusitis, Rhinosinusitis Acute, Cystitis Chronic
- rHuPH20Phase 35 trials
Bristol Myers Squibb · Melanoma, Relapsing-remitting Multiple Sclerosis, Clear Cell Renal Cell Carcinoma
Largest recruiting Phase 3 trials
- Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)Pivotal-lookingRecruiting
MAXVAX Biotechnology Limited Liability CompanyIndustry
NCT07272434 · 25,000 participants (planned) · Start Oct 22, 2025 · Primary completion Jul 31, 2026
Drug: Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell); Placebo (Saline solution) · For: Respiratory Syncytial Virus (RSV)
Sites: Guangzhou, China; Shijiazhuang, China; Zhengzhou, China · 8 sites in all
- Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan AfricaPivotal-lookingRecruiting
Biofabri, S.LIndustry
NCT04975178 · 7,120 participants (planned) · Start Oct 17, 2022 · Primary completion Feb 2029
Drug: MTBVAC; BCG · For: Tuberculosis
Sites: Worcester, South Africa
- Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and OlderPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07890454 · 6,000 participants (planned) · Start Oct 28, 2026 · Primary completion Dec 28, 2027
Drug: IIV-HD (standalone); NVXC19 (EU licensed, standalone) and 2 more · For: Immunization; Healthy Volunteers; COVID-19 Immunization and 1 more
Sites: Wroclaw, Poland; Gdynia, Poland
- A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07071623 · 4,580 participants (planned) · Start Nov 10, 2025 · Primary completion Oct 18, 2027
Drug: MK-8527; Emtricitabine/tenofovir disoproxil (FTC/TDF) and 2 more · For: Human Immunodeficiency Virus (HIV); HIV Pre-Exposure Prophylaxis
Sites: Homabay County, Kenya; Thika, Kenya; Nairobi, Kenya · 30 sites in all
- Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in ChinaPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07710872 · 4,568 participants (planned) · Start Aug 22, 2026 · Primary completion Mar 13, 2028
Drug: MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA); Menhycia® (ACYW135 Meningococcal Conjugate Vaccine [CRM197]) (CanSino Biologics Inc., China) · For: Meningococcal Infection; Healthy Volunteers
Sites: Huanggang, China; Jianli City, Jingzhou City, China; Jingxi, China · 8 sites in all
- Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental OxygenPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT05624450 · 3,527 participants (planned) · Start Dec 13, 2022 · Primary completion Nov 4, 2027
Drug: Tozorakimab; Placebo · For: Viral Lung Infection and Acute Respiratory Failure
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 473 sites in all
- A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07629440 · 3,230 participants (planned) · Start May 29, 2026 · Primary completion Jun 5, 2029
Drug: PG4; 20-valent pneumococcal conjugate vaccine (20vPnC) · For: Pneumococcal Disease
Sites: Birmingham, Alabama; Fayetteville, Arkansas; Jonesboro, Arkansas · 134 sites in all
- A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06667700 · 3,082 participants (planned) · Start Dec 2, 2024 · Primary completion Jan 26, 2031
Drug: Molnupiravir; Placebo · For: Coronavirus Disease (COVID-19)
Sites: Cullman, Alabama; Paradise Valley, Arizona; Phoenix, Arizona · 230 sites in all
- Clinical Trial of 13-Valent Pneumococcal Conjugate VaccinePivotal-lookingRecruiting
Sinovac Life Sciences Co., Ltd.Industry
NCT06617715 · 3,080 participants (planned) · Start Oct 23, 2024 · Primary completion May 12, 2026
Drug: Sinovac PCV13; Prevnar® · For: Pneumococcal Infectious Disease
Sites: Zhengzhou, China
- A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of AgePivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07851246 · 3,000 participants (planned) · Start Oct 1, 2026 · Primary completion Jul 9, 2027
Drug: mRNA Seasonal Flu vaccine; Comparator 1 and 1 more · For: Influenza, Human
Sites: Glendale, Arizona; Tucson, Arizona; San Diego, California · 12 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.